NCT03445533 2022-11-08A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory MelanomaIdera Pharmaceuticals, Inc.Phase 3 Terminated481 enrolled 22 charts